@article{0c3abf5c6b6b4b7aa5641f62f3d93079,
title = "Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition",
abstract = "Background: Excess body fatness and hyperinsulinemia are both associated with an increased risk of postmenopausal breast cancer. However, whether women with high body fatness but normal insulin levels or those with normal body fatness and high levels of insulin are at elevated risk of breast cancer is not known. We investigated the associations of metabolically defined body size and shape phenotypes with the risk of postmenopausal breast cancer in a nested case–control study within the European Prospective Investigation into Cancer and Nutrition. Methods: Concentrations of C-peptide—a marker for insulin secretion—were measured at inclusion prior to cancer diagnosis in serum from 610 incident postmenopausal breast cancer cases and 1130 matched controls. C-peptide concentrations among the control participants were used to define metabolically healthy (MH; in first tertile) and metabolically unhealthy (MU; >1st tertile) status. We created four metabolic health/body size phenotype categories by combining the metabolic health definitions with normal weight (NW; BMI < 25 kg/m2, or WC < 80 cm, or WHR < 0.8) and overweight or obese (OW/OB; BMI ≥ 25 kg/m2, or WC ≥ 80 cm, or WHR ≥ 0.8) status for each of the three anthropometric measures separately: (1) MHNW, (2) MHOW/OB, (3) MUNW, and (4) MUOW/OB. Conditional logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results: Women classified as MUOW/OB were at higher risk of postmenopausal breast cancer compared to MHNW women considering BMI (OR = 1.58, 95% CI = 1.14–2.19) and WC (OR = 1.51, 95% CI = 1.09–2.08) cut points and there was also a suggestive increased risk for the WHR (OR = 1.29, 95% CI = 0.94–1.77) definition. Conversely, women with the MHOW/OB and MUNW were not at statistically significant elevated risk of postmenopausal breast cancer risk compared to MHNW women. Conclusion: These findings suggest that being overweight or obese and metabolically unhealthy raises risk of postmenopausal breast cancer while overweight or obese women with normal insulin levels are not at higher risk. Additional research should consider the combined utility of anthropometric measures with metabolic parameters in predicting breast cancer risk.",
keywords = "body mass index, breast cancer, concentrations of C-peptide, metabolic health, waist circumference, waist-to-hip ratio",
author = "Y. Mahamat-Saleh and S. Rinaldi and R. Kaaks and C. Biessy and Gonzalez-Gil, {E. M.} and N. Murphy and C. Le Cornet and Huerta, {J. M.} and S. Sieri and A. Tj{\o}nneland and L. Mellemkj{\ae}r and M. Guevara and K. Overvad and A. Perez-Cornago and S. Tin Tin and L. Padroni and V. Simeon and G. Masala and A. May and E. Monninkhof and S. Christakoudi and Heath, {A. K.} and K. Tsilidis and A. Agudo and Schulze, {M. B.} and J. Rothwell and C. Cadeau and S. Severi and E. Weiderpass and Gunter, {M. J.} and L. Dossus",
note = "Funding Information: Yahya Mahamat‐Saleh is a postdoctoral scientist at the International Agency for Research on Cancer and supported by the Fondation ARC pour la recherche sur le cancer ARCPOST‐DOC2021080004105. The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G{\'e}n{\'e}rale de l'Education Nationale, Institut National de la Sant{\'e} et de la Recherche M{\'e}dicale (INSERM; France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam‐Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF; Germany); Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc{\'i}a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Sk{\aa}ne and V{\"a}sterbotten (Sweden); Cancer Research UK (14,136 to EPIC‐Norfolk; C8221/A29017 to EPIC‐Oxford), Medical Research Council (1,000,143 to EPIC‐Norfolk; MR/M012190/1 to EPIC‐Oxford; United Kingdom). Publisher Copyright: {\textcopyright} 2023 World Health Organization; licensed by John Wiley & Sons Ltd. Cancer Medicine published by Wiley Periodicals LLC.",
year = "2023",
doi = "10.1002/cam4.5896",
language = "English",
volume = "12",
pages = "12668--12682",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "JohnWiley & Sons Ltd",
number = "11",
}